Novavax (NVAX) closed at $9.62 in the latest trading session, marking a -1.23% move from the prior day. The stock exceeded the S&P 500, which registered a loss of 1.51% for the day. Meanwhile, the Dow ...

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look ...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Moderna (NASDAQ:MRNA) and the best and ...

As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, ...

Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of ...

A federal court injunction put a check on Health Secretary Robert F. Kennedy Jr.'s rapid assault on U.S. vaccine recommendations, but months of turmoil and misinformation have sown doubt about ...

U.S. District Judge Brian Murphy in ‌Boston sided with the American Academy of Pediatrics and other medical groups, which said health regulators had acted unlawfully ​to carry out Kennedy's agenda of ...

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in ...

In a wide-ranging conversation on the podcast Inside Indian America, the Shah Capital founder reflects on markets, geopolitics, AI, and lessons from a three-decade career.

If you're looking for the most hated stocks on Wall Street, start with this list. All seven companies are worth more than $1 billion but have more than 30% of their available shares held by short ...

Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q4 therapeutics earnings season.

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look ...